Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

JSPR vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

JSPR Captures Overall Composite Edge (33.8 SELL vs 58.9 HOLD), While LCTX Leads 3–2 on Growth & Valuation Pillars

JSPR Overall Winner 6-Pillar Tally: JSPR 2 – 3 LCTX (1 Tie) Matrix Metrics: JSPR 3 – 7 LCTX

As of Nov 19, 2026, Jasper Therapeutics, Inc. (JSPR) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (33.8/100 SELL vs. 58.9/100 HOLD) after splitting the core matrix 3–7 (led by Balance Sheet & Cash Flow, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. JSPR trades at $10.75 (N/M Forward P/E, 0.0% operating margin) versus LCTX at $0.82 (30.7x Forward P/E, -280.3% operating margin).

  • Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. JSPR 33.8/100 SELL), JSPR captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY).
  • Technical & Structure Timing Caution: JSPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About JSPR vs LCTX
JSPR NASDAQ Head-to-Head Winner
Jasper Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$10.75
-6.68% 1D
Market Cap $12.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 8.00β · 11818% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 50.0 Fund 34.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (396.2% over 20 days), RSI 66
RSI-14: 65.7 · SMA20: $7.00 · SMA50: $3.14
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $0.98 · SMA50: $0.98

6-Pillar Scorecard Institutional Category Breakdown (JSPR 2 – 3 LCTX)

Columns: Metric · JSPR · LCTX
1. Valuation Multiples LCTX
Forward P/E N/M 30.7x
Trailing P/E N/M 30.7x
PEG Ratio N/M 10.64x
EV / Revenue N/M 16.3x
2. Growth & Scale LCTX
Revenue Growth (YoY) +0.0% -61.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $11M
Market Cap $12.8M $212.1M
3. Profitability & Quality LCTX
Gross Margin N/A -95.0%
Operating Margin 0.0% -280.3%
Net Profit Margin 0.0% 16.2%
Return on Equity (ROE) -255.1% 4.3%
4. Balance Sheet & Cash Flow JSPR
Cash Generation (TTM) N/A -$24M
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.0M Net Cash $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning JSPR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 439.3% (45th %ile) 896.2% (100th %ile)
Put/Call OI Skew N/A 1.10x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: JSPR (3) vs LCTX (7)
Institutional Metric JSPR LCTX Criterion Row Edge
Market Capitalization
Scale
$12.8M $212.1M Larger Scale LCTX
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
+0.0% -61.0% Higher Growth JSPR
Operating Margin (TTM)
Profitability
0.0% -280.3% Higher Margin JSPR
Net Profit Margin
Profitability
0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
-255.1% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
62% ($0–$17) 4% ($1–$2) Stronger Trend JSPR
Beta / 30D Volatility
Risk Regime
8.00β · 11818% Vol 1.36β · 79% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
33.8 / 100 (SELL) 58.9 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 10.64x PEG · 16.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($7.0M Net Cash) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon JSPR +2045.49 pp
JSPR: +2031.67% · LCTX: -13.82%
3M Horizon JSPR +1425.47 pp
JSPR: +1401.4% · LCTX: -24.07%
6M Horizon JSPR +1169.83 pp
JSPR: +1131.95% · LCTX: -37.88%
1Y Horizon JSPR +541.1 pp
JSPR: +487.43% · LCTX: -53.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on JSPR vs LCTX. Trailing 12-month operating profitability (JSPR 0.0% vs LCTX -280.3%) and valuation multiples (JSPR N/M vs LCTX 30.7x Forward P/E) are benchmarked directly in Pillar 4 below.

JSPR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-255.1% · N/M
LCTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin-95.0%
Op. Margin-280.3%
ROE / Fwd P/E4.3% · 30.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
JSPR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 439.3%
IV Percentile 45th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact JSPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
JSPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ JSPR vs LCTX Key Questions & Quantitative Answers

As of Nov 19, 2026, Jasper Therapeutics, Inc. (JSPR) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (33.8/100 SELL vs. 58.9/100 HOLD) after splitting the core matrix 3–7 (led by Balance Sheet & Cash Flow, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. JSPR trades at $10.75 (N/M Forward P/E, 0.0% operating margin) versus LCTX at $0.82 (30.7x Forward P/E, -280.3% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. JSPR 33.8/100 SELL), JSPR captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY). Technical & Structure Timing Caution: JSPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LCTX leads the Growth & Scale pillar: JSPR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). On trailing 12-month operating scale, JSPR generates N/A in USD-normalized revenue versus $11M for LCTX. In operating R&D and SG&A reinvestment, JSPR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

LCTX screens cheaper on headline valuation multiples. JSPR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against JSPR (-255.1% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, JSPR carries 439.3% implied volatility (45th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.00β · 11818% Vol realized risk). By comparison, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.